Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Background: CVD in obesity and T2DM are associated with endothelial activation, elevated plasma vascular inflammation markers and a prothrombotic state. We examined the contribution of FFA to these abnormalities following a 48-hour physiological increase in plasma FFA to levels of obesity and diabetes in a group of healthy subjects. Methods: 40 non-diabetic subjects (age = 38 ± 3 yr, BMI = 28 ± 1 kg/m 2, FPG = 95 ± 1 mg/dl, HbA 1c = 5.3 ± 0.1%) were admitted twice and received a 48-hour infusion of normal saline or low-dose lipid. Plasma was drawn for intracellular (ICAM-1) and vascular (VCAM-1) adhesion molecules-1, E-selectin (sE-S), myeloperoxidase (MPO) and total plasminogen inhibitor-1 (tPAI-1). Insulin sensitivity was measured by a hyperglycemic clamp (M/I). Results: Lipid infusion increased plasma FFA to levels observed in obesity and T2DM and reduced insulin sensitivity by 27% (p = 0.01). Elevated plasma FFA increased plasma markers of endothelial activation ICAM-1 (138 ± 10 vs. 186 ± 25 ng/ml), VCAM-1 (1066 ± 67 vs. 1204 ± 65 ng/ml) and sE-S (20 ± 1 vs. 24 ± 1 ng/ml) between 13-35% and by ≥ 2-fold plasma levels of myeloperoxidase (7.5 ± 0.9 to 15 ± 25 ng/ml), an inflammatory marker of future CVD, and tPAI-1 (9.7 ± 0.6 to 22.5 ± 1.5 ng/ml), an indicator of a prothrombotic state (all p ≤ 0.01). The FFA-induced increase was independent from the degree of adiposity, being of similar magnitude in lean, overweight and obese subjects. Conclusions: An increase in plasma FFA within the physiological range observed in obesity and T2DM induces markers of endothelial activation, vascular inflammation and thrombosis in healthy subjects. This suggests that even transient (48-hour) and modest increases in plasma FFA may initiate early vascular abnormalities that promote atherosclerosis and CVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Endothelial Function and Dysfunction: Testing and Clinical Relevance
Deanfield, J. E., Halcox, J. P., & Rabelink, T. J. (2007) · Circulation · doi:10.1161/circulationaha.106.652859 · Cited by 2,710
Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.-W., Karin, M., & Shoelson, S. E. (2001) · Science · doi:10.1126/science.1061620 · Cited by 1,884 · cited 1×
“Endothelial dysfunction has been reported to be reversible with lifestyle changes [60], anti-inflammatory agents such as salicylates [61] or by insulin-sensitizers such as thiazolidinediones [62].”
BackgroundA placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 1×
“Endothelial dysfunction has been reported to be reversible with lifestyle changes [60], anti-inflammatory agents such as salicylates [61] or by insulin-sensitizers such as thiazolidinediones [62].”
BackgroundSelf-citationCollins, T., Read, M. A., Neish, A. S., Whitley, M. Z., Thanos, D., & Maniatis, T. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.10.7542214 · Cited by 1,718
Esposito, K., Pontillo, A., Di Palo, C., Giugliano, G., Masella, M., Marfella, R., & Giugliano, D. (2003) · JAMA · doi:10.1001/jama.289.14.1799 · Cited by 1,511 · cited 1×
“Endothelial dysfunction has been reported to be reversible with lifestyle changes [60], anti-inflammatory agents such as salicylates [61] or by insulin-sensitizers such as thiazolidinediones [62].”
BackgroundDaugherty, A., Dunn, J. L., Rateri, D. L., & Heinecke, J. W. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117342 · Cited by 1,269 · cited 2×
“MPO and its reactive oxygen species (ROS) are enriched in human atheroma plaques [22-26] and increase within the area of infarct after an acute myocardial infarction [24,27].”
BackgroundRidker, P. M., Hennekens, C. H., Roitman-Johnson, B., Stampfer, M. J., & Allen, J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09032-6 · Cited by 1,229 · cited 2×
“Plasma measurement of cell adhesion molecules are accepted markers of endothelial dysfunction and vascular disease [9-16].”
BackgroundHazen, S. L., & Heinecke, J. W. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119379 · Cited by 842 · cited 2×
“MPO and its reactive oxygen species (ROS) are enriched in human atheroma plaques [22-26] and increase within the area of infarct after an acute myocardial infarction [24,27].”
BackgroundNew Markers of Inflammation and Endothelial Cell Activation: Part I
Szmitko, P. E., Wang, C.-H., Weisel, R. D., de Almeida, J. R., Anderson, T. J., & Verma, S. (2003) · Circulation · doi:10.1161/01.cir.0000089190.95415.9f · Cited by 738 · cited 11×
“Background: CVD in obesity and T2DM are associated with endothelial activation, elevated plasma vascular inflammation markers and a prothrombotic state.”
BackgroundInfluentialBiomarkers of Endothelial Dysfunction and Risk of Type 2 Diabetes Mellitus
Meigs, J. B. (2004) · JAMA · doi:10.1001/jama.291.16.1978 · Cited by 643 · cited 1×
“Recently, ICAM-1 and E-selectin were reported to predict future development of T2DM, even after accounting for classical risk factors such as age, BMI, family history of T2DM, hsCRP and others [51].”
BackgroundSchmitz-Peiffer, C., Craig, D. L., & Biden, T. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.24202 · Cited by 592
Kashyap, S., Belfort, R., Gastaldelli, A., Pratipanawatr, T., Berria, R., Pratipanawatr, W., Bajaj, M., Mandarino, L., DeFronzo, R., & Cusi, K. (2003) · Diabetes · doi:10.2337/diabetes.52.10.2461 · Cited by 503
Self-citationZhang, R., Brennan, M.-L., Shen, Z., MacPherson, J. C., Schmitt, D., Molenda, C. E., & Hazen, S. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m209124200 · Cited by 432 · cited 1×
“The mechanisms by which MPO may promote atherogenesis include conversion of LDL into more atherogenic oxidized particles (oxLDL), oxidative modification of apolipoprotein A-I that results in a dysfunctional HDL and reduction of EC nitric oxide availability resulting in endothelial dysfunction [21-24,26,53-55].”
BackgroundSavoia, C., & Schiffrin, E. L. (2007) · Clinical Science · doi:10.1042/cs20060247 · Cited by 326 · cited 3×
“Atherosclerosis in obesity, metabolic syndrome and T2DM is initiated by damage/activation of the endothelium [2,4,8].”
BackgroundThukkani, A. K., McHowat, J., Hsu, F.-F., Brennan, M.-L., Hazen, S. L., & Ford, D. A. (2003) · Circulation · doi:10.1161/01.cir.0000104564.01539.6a · Cited by 194
Hak, A. E., Pols, H. A. P., Stehouwer, C. D. A., Meijer, J., Kiliaan, A. J., Hofman, A., Breteler, M. M. B., & Witteman, J. C. M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7873 · Cited by 184 · cited 1×
“E-selectin concentrations are elevated in obesity [45-47], chronic renal failure [48], in lean and obese subjects genetically predisposed to T2DM [39,49] and in T2DM [16,50].”
BackgroundKashyap, S. R., Belfort, R., Berria, R., Suraamornkul, S., Pratipranawatr, T., Finlayson, J., Barrentine, A., Bajaj, M., Mandarino, L., DeFronzo, R., et al. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00541.2003 · Cited by 103 · cited 2×
“This observation made evident that a mild physiological increase in plasma FFA by a short-term (48-hours) low-dose lipid infusion is capable of profound metabolic effects in healthy humans, consistent with prior observations by our group [41,42].”
MethodResultSelf-citationZhang, W.-Y., Schwartz, E., Wang, Y., Attrep, J., Li, Z., & Reaven, P. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000200226.53994.09 · Cited by 70 · cited 1×
“Human monocytes exposed for just 48 hours to excessive lipids have a dose-dependent increase in intercellular ROS and increased adhesion to ECs, mediated by an increase in integrin CD11b cell surface expression [58].”
Background
Cited by
Cusi, K. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 911
Self-citationInsulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Di Pino, A., & DeFronzo, R. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00141 · Cited by 535
Role of free fatty acids in endothelial dysfunction
Ghosh, A., Gao, L., Thakur, A., Siu, P. M., & Lai, C. W. K. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0357-5 · Cited by 414
Thrombomodulin and its role in inflammation
Conway, E. M. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-011-0282-8 · Cited by 322
The Role of Adipose Tissue and Lipotoxicity in the Pathogenesis of Type 2 Diabetes
Cusi, K. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0122-6 · Cited by 300
Self-citation
Metadata
- Authors
- Mathew, M., Tay, E., & Cusi, K.
- Venue
- Cardiovascular Diabetology
- Published
- 2010-02-16
- Volume
- 9
- Issue
- 1
- Pages
- 9-9
- ISSN
- 1475-2840 (ISSN-L)
- OpenAlex
- W2109246857
- Cited by
- 142
- References
- 19
- FWCI
- 9.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.